Skip to content
Brand AI

Shenzhen Chipscreen Biosciences Co.

Controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile1 entries

  1. 2025

    Chia Tai Tianqing challenges core product chidamide patent; patent partly invalidated

    Nanjing Chia Tai Tianqing filed invalidation requests against patents related to Chipscreen Biosciences' core product chidamide. In September 2025, a patent for the PTCL indication was declared wholly invalid; in May 2026, a composition patent was partially invalidated. The product accounts for more than 60% of revenue, and the stock fell more than 5% intraday. Patent partially invalidated.

    Source